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Abstract
TNF receptor-associated periodic syndrome (TRAPS) is a
dominantly inherited disease caused by missense mutations in the
TNF receptor 1 (TNFR1) gene. Patients suffer from periodic bouts
of severe abdominal pain, localised inflammation, migratory rashes,
and fever. More than 40 individual mutations have been identified,
all of which occur in the extracellular domain of TNFR1. In the
present review we discuss new findings describing aberrant
trafficking and function of TNFR1 harbouring TRAPS mutations,
challenging the hypothesis that TRAPS pathology is driven by
defective receptor shedding, and we suggest that TNFR1 might
acquire novel functions in the endoplasmic reticulum, distinct from
its role as a cell surface receptor. We also describe the clinical
manifestations of TRAPS, current treatment regimens, and the
widening array of patient mutations.
Introduction
The TNF-receptor associated periodic syndrome (TRAPS) is
a dominantly inherited periodic fever syndrome characterised
by prolonged episodic fevers, multiorgan involvement, and
resistance to colchicine. Over 40 missense mutations in TNF
receptor 1 (TNFR1), the prototypical proinflammatory receptor,
have been associated with TRAPS. In the present review we
discuss recent evidence that the unifying molecular defect in
TRAPS-associated mutant TNFR1 is receptor misfolding and
retention in the endoplasmic reticulum (ER). This finding
constitutes a novel mechanism of receptor misbehaviour in
genetic disease and suggests hitherto unexpected functions
for intracellularly retained receptors in promoting inflammation.
Periodic fevers and TRAPS
The periodic fevers are a group of disorders characterised by
unprovoked attacks of fever and localised inflammation that
can affect multiple organ systems [1]. There are several
periodic fever syndromes that are inherited in a recessive
manner, such as familial Mediterranean fever (FMF) caused
by mutations in the gene encoding the neutrophil-specific
protein Pyrin [2]. Most evidence currently suggests that pyrin
negatively regulates the production of IL-1β – a major
proinflammatory cytokine of the innate immune response [3].
IL-1β is generated from its proform via cleavage by caspase-1,
which occurs in a specialised IL-1 activating protein complex
termed the inflammasome [4-6]. FMF-associated mutations in
pyrin are thought to exert less inhibition of IL-1β processing
[7]. Another such recessive disease is hyperimmunoglobu-
linemia-D with periodic fever syndrome, which arises due to
mutations in mevalonate kinase – a key enzyme in cholesterol
biosynthesis and the synthesis of nonsterol isoprenoid
molecules [8,9]. The exact molecular basis for the disease
resulting from these mutations, however, remains unclear.
The molecular basis of two groups of dominant periodic fever
syndrome has been identified. Dominant mutations in the
CIAS1 gene are associated with a heterogeneous group of
inflammatory conditions encompassing Muckle–Wells syn-
drome, familial cold autoinflammatory syndrome, and the
neonatal onset multisystem inflammatory disease [10]. CIAS1
is one of the intracellular sensors that activate the inflamma-
some, and it is thought that CIAS1 mutations associated with
these diseases might lead to its constitutive activation.
Through studies of cohorts of patients with dominantly
inherited familial periodic fevers, formerly classified as
dominant periodic syndrome and familial Hibernian fever,
mutations in the TNFR1 gene on chromosome 12p13 were
identified. These patients were therefore classified as having
TRAPS [11-13]. TNFR1 is the archetypal proinflammatory
receptor and a member of the TNF receptor superfamily – a
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large group of proteins with homology in their extracellular
domains, which are involved in a variety of processes
including inflammation, T-cell activation, B-cell homeostasis,
and osteoclast function.
The mean age of onset for TRAPS is 3 years, but diagnoses
have been made at ages ranging from 2 weeks to 53 years.
Unlike FMF, in which attacks are predictably less than 5 days
in duration, febrile attacks in TRAPS can last from a few days
to months, with an average duration of 21 days. There is no
fixed periodicity between attacks; they can occur as
frequently as every 5–6 weeks, or patients can be symptom-
free for months to years. Attacks are usually unprovoked, but
they have been reported to be triggered or aggravated by
several factors, such as local injury, minor infection, stress,
exercise, and hormonal changes – attacks are often relieved
during pregnancy [14,15]. The most common symptoms
associated with an attack are fever, a migrating radial rash on
the limbs, and extreme abdominal and muscle pain, but
symptoms can also include conjunctivitis, headaches, chest
pain, myalgia, arthralgia, and less commonly arthritis and
other inflammatory manifestations including fasciitis, myo-
carditis, sacroiliitis, pharyngitis, and stomatitis [16-19]. The
most serious complication associated with TRAPS is
systemic amyloidosis – extracellular deposits of an insoluble
cleavage product of the acute-phase reactant protein serum
amyloid A. Many patients with renal amyloidosis develop
nephrotic syndrome and progress to renal failure.
Laboratory findings in TRAPS are in accordance with a
typical inflammatory episode: high levels of C-reactive protein,
neutrophilia, moderate complement activation, raised mean
erythrocyte sedimentation rate, and, in some cases, marginally
raised IgA and IgD levels [16,17,20-22]. Importantly, acute
phase proteins can also be elevated between attacks,
suggesting that subclinical inflammation may be more chronic
[23]. Cytokine profiling of a small group of TRAPS patients
revealed that IL-6 was relatively more elevated than TNFα, when
compared with a group of rheumatoid arthritis patients [24].
Corticosteroids, colchicine, and high doses of nonsteroidal
anti-inflammatory drugs have all been used to treat TRAPS
with varied success. Unlike FMF, TRAPS patients generally
respond poorly to colchicine [15,25]. TRAPS symptoms can
be relieved with high doses of prednisolone (> 20 mg),
although efficacy fades with time [13]. The greatest success
in the treatment of TRAPS has been observed with
etanercept (soluble TNFR2 fused to the Fc region of human
IgG) in a number of small uncontrolled clinical trials [26-32].
Treatment with infliximab (anti-TNFα) in some cases, how-
ever, led to exacerbation of the disease [33,34]. Interestingly,
anakinra (an IL-1 receptor antagonist) was remarkably
successful in the treatment of a TRAPS patient resistant to
anti-TNF therapy [35]. Since no randomised controlled trials
of therapy have been carried out for this rare syndrome, there
is currently no single recommended treatment.
Mutations in TNFR1 associated with TRAPS
The TRAPS mutations were discovered through screening
programmes of patients and families who had previously
presented with unexplained periodic fever. Although initial
mutations were identified in patients of Irish descent (which
gave rise to its original name of familial Hibernian fever), it is
increasingly evident that the disease is ethnically diverse –
TRAPS mutations are being discovered in Japanese, Turkish,
and Arabic populations, hinting at underdiagnosis in these
populations rather than prior absence [36-38].
Discovery of the mutations in TNFR1 associated with TRAPS
was a seminal finding that connected this poorly understood
disease with one of the canonical receptors that mediates
inflammation [13]. TNFR1 is a prototypic member of the TNF
receptor superfamily, characterised by a distinct pattern of
disulphide bonding in the extracellular cysteine-rich domains
(CRDs). TNFR1 has four CRDs in its extracellular region and
an intracellular death domain that can initiate signalling
leading to two opposing outcomes – inflammation and cell
survival, versus cell death via apoptosis – depending on the
cell type and intracellular milieu [39].
The crystal structure of TNFR1 in complex with one of its
ligands, lymphotoxin-α (TNFβ), demonstrates that the majority
of contact residues between ligand and receptor are located
in CRD2 [40]. Recent work has demonstrated that members
of the TNF receptor superfamily, including TNFR1, can self-
associate in the membrane in the absence of ligand. Self-
association is mediated by the so-called preligand assembly
domain, which is located in the first CRD [41]. Interestingly, a
structure of TNFR1 in the absence of its ligand TNF revealed
a dimer of two receptors with extensive contacts between
receptors in CRD1 [42].
Figure 1 illustrates the location of the TRAPS mutations, which
occur predominantly in CRD1 and CRD2; there are no known
TRAPS mutations in the transmembrane or intracellular
domain of TNFR1. A definitive list of all the TRAPS mutations
can be found on the INFEVERS website [43]. Many of the
mutations involve cysteine residues involved in intramolecular
disulphide bonds, and others occur at residues predicted to
have a pronounced effect on the overall secondary structure,
such as the introduction or removal of a proline (P46L, L67P,
S86P, R92P), or residues involved in hydrogen bonding
between loops of the receptor (T50M, I170N) [44]. Other
than single base pair changes, there is a splicing mutation that
introduces an extra four amino acids [45], a single amino acid
deletion [20], and an inframe interstitial deletion of nine amino
acids, all in the extracellular domain [16]. Remarkably, there
are no mutations encoding large truncations or deletions
within the receptor, which suggests that synthesis of the
mutant protein is important for disease pathogenesis.
In addition to the TNFR1 mutations identified in TRAPS that
do not occur in the normal population, two rare coding
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sequence variants in TNFR1 that alter single amino acids
have been identified as low-penetrance risk factors for
TRAPS. The R92Q amino acid substitution is carried at a low
frequency (~2%) in North American and Irish populations
[23,45], and the P46L mutation was found in 9% of African
populations [46]. TRAPS patients with these polymorphisms
have a milder syndrome, with less severe flares and almost no
incidence of amyloidosis. The R92Q mutation has also been
linked with other diseases associated with inflammation, such
as rheumatoid arthritis and atherosclerosis [47-49]. Although
the penetrance of TRAPS is high among patients with the
rare TNFR1 mutations (>80%), several asymptomatic family
members have been reported, suggesting that other genetic
and/or environmental factors also play a role in triggering the
symptoms of TRAPS.
Molecular basis of TRAPS: new answers and
new questions
In light of our current understanding of TNF receptor signal-
ling, this disease presents a paradox. TNFα is a prototypic
proinflammatory cytokine, and exerts most of its biologic
effects through TNFR1. The question therefore beckons of
how these mutations, which would be predicted to lead to a
nonfunctional receptor and therefore less TNFR1 signalling,
can drive a proinflammatory condition. Following the earliest
research, several hypotheses were proposed [13,31].
Firstly, it was suggested that the mutations might render the
receptor constitutively active. Since cysteines are often
affected, it seemed possible that receptors could be cross-
linked at the surface through the formation of aberrant
disulphide bonds between receptor pairs, resulting in
constitutive TNFR1 signalling.
A second theory was that TRAPS mutations increase the
affinity of the receptor for TNFα – a concept difficult to
rationalise as mutations would be predicted to have a
profound effect on the overall structure of TNFRI, and which
is not supported by binding measurements of radiolabelled
TNFα to patients’ leukocytes [31].
A third hypothesis is that TNFR1 mutations in TRAPS cause
impaired cleavage of membrane-bound TNFR1, leading to
reduced serum levels of soluble TNFR1. This hypothesis was
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Figure 1
TNF receptor-associated periodic syndrome mutations in TNF receptor 1. Schematic of TNF receptor-associated periodic syndrome (TRAPS)
mutations in TNF receptor 1 (TNFR1) illustrating the extreme clustering of mutations towards cysteine-rich domains CRD1 and CRD2. 
(a) The preligand assembly domain (PLAD), ligand binding domain, and other structural features of TNFR1 are highlighted. (b) A line model of
CRD1 and CRD2 of TNFR1, with the sites of TRAPS mutations and amino acid (aa) changes indicated (red boxes).
supported by initial observations that some TRAPS patient
cells are resistant to phorbol-myristate acetate-induced
‘shedding’ of TNFR1 from the surface, and that serum from
TRAPS patients contained reduced levels of circulating
soluble TNFR1, relative to controls [13].
Functional buffering of TNF by soluble TNFR1, generated
through metalloprotease-dependent cleavage of cell surface
TNFR1, is a well-defined phenomenon that appears to occur
constitutively, but can also occur in response to several
cytokines and TNFα itself (reviewed in [50]). The resultant
reservoir of free soluble TNFR1 has a homeostatic effect on
signalling that is twofold: decreasing the number of sites
available on the membrane for binding, and providing a pool
of receptors to sequester TNFα [51]. Shed TNFR1 can
function as a soluble inhibitor of TNF and forms the basis for
using etanercept to treat TRAPS. In addition, it has been
shown that full-length TNFR1 is released in exosome-like
microvesicles, which would also be expected to contribute to
functional buffering of TNFα signalling [52].
In an attempt to mimic the accepted TRAPS ‘phenotype’ of
impaired receptor shedding, Xanthoulea and colleagues
created a knock-in mouse that expressed a nonsheddable
form of TNFR1 [53]. Mice with either heterozygous or homo-
zygous expression of the otherwise functional receptor
showed enhanced TNF signalling, with spontaneous hepatitis
and increased susceptibility and severity of induced arthritis.
These data indicate that either a failure to cleave TNFR1 from
the cell surface or a failure to form soluble TNFR1 can pre-
dispose spontaneous inflammation – supporting an anti-
inflammatory role for soluble TNFR1.
Several metalloproteases have been implicated in the cleavage
of membrane-bound TNFR1 [54]. Since these enzymes target
a sequence in the membrane proximal region of the receptor,
it seems unlikely that mutations in domains away from this
region could cause complete inhibition of cleavage. Despite
this, much of the early functional work on TRAPS
concentrated on this concept, which has been termed the
‘shedding hypothesis’ (Figure 2). The shedding defect in
TRAPS patients’ cells, however, was subsequently found to
be variable, especially between the type of cells studied, and
did not occur in all cases [55]. Since shedding can also
result from the secretion of exosomal vesicles, the observed
defect could equally be due to a defect in this pathway, which
can be triggered from within the cell [52]. Alternative
explanations for the pathogenesis of inflammation in TRAPS
have therefore been sought.
New concepts in the understanding of TRAPS have arisen
from studies by our laboratories, and others, showing that
receptor misfolding and mislocalisation is a universal feature
of TNFR1 mutations in TRAPS. TNF binding studies in cells
and in vitro have demonstrated that the TRAPS-associated
mutant TNFR1 is unable to bind to TNF. Furthermore, we and
other workers have now demonstrated that the mutant
receptors fail to localise to the cell surface [56]. This defect
was also observed in cells from TNFR1 ‘knock-in’ mice
expressing the T50M mutation [56]. Significantly, the TRAPS-
associated mutant TNFR1 was specifically retained in the ER –
the retention site for misfolded proteins in the secretory pathway.
The molecular basis of intracellular retention of TRAPS-
associated mutants appears to be misfolding – based on the
findings that the mutant receptors fail to bind TNF, they do
not make normal preligand assembly domain-dependent
interactions with wild-type TNFR1, and, due to aberrant
intermolecular disulphide bonds, can form high-order
oligomers [56]. At higher levels of expression, it is probable
that TRAPS-associated mutant TNFR1 exits the ER through
the process of ER-associated degradation and accumulates
in cytoplasmic punctate structures that colocalise with
chaperone proteins termed ‘aggresomes’, destined for
proteasome-mediated disposal [56,57]. Most of this work,
however, has been carried out using cDNA transfected cells,
which some may argue are a poor model for ER studies.
Hence, it will be interesting to see data to support the ER
retention model from future studies using cells from TRAPS
patients.
Unlike all the TRAPS mutations, the rare TNFR1 variant
R92Q behaves similarly to wild-type TNFR1 in terms of ligand
binding and trafficking, indicating that the mechanism of
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Figure 2
The shedding hypothesis. Mutations in TNF receptor 1 (TNFR1) were
thought to impair cleavage of TNFR1 from the membrane by
membrane metalloproteases, leading to depletion in the pool of soluble
TNF (sTNF) receptor (sTNFR1). In this model for TNF receptor-
associated periodic syndrome mutations (TRAPS), both soluble and
membrane-bound TNFα are no longer sequestered by the soluble
receptor, resulting in overstimulation of membrane-bound TNFR1. NO,
nitric oxide; ROS, reactive oxygen species.
disease associated with this variant receptor is probably
different to that of the mutations strictly associated with
TRAPS. Since TRAPS is an autosomal dominant disease,
with patients generally carrying one wild-type allele and one
mutant allele, it was important to test the effects of
coexpression of mutant and wild-type TNFR1. Despite the
dramatic defects in TRAPS-associated mutant TNFR1, trans-
fection studies found that the mutant TNFR1 did not
significantly interfere with the trafficking or function of the
wild-type allele [56].
These findings suggest that inflammation in TRAPS results
from either haploinsufficiency of wild-type receptors or some
critical function gained by the mutant TNFR1. In our opinion,
haploinsufficiency of surface or soluble TNFR1 seems
unlikely given the fact that no known TRAPS mutations lead
to complete lack of protein expression. New studies will
probably focus on the consequences of intracellularly retained
mutant TNFR1 in TRAPS. It is known that TRAPS-associated
mutants have functional death domains and retain the ability
to activate NF-κB [56-59], but, as mentioned previously,
mutant receptors do not seem to induce increased NF-κB
transactivation in transfected cells.
Accumulation of mutant TNFR1 in the ER may trigger the ER
stress response, which could directly or indirectly lead to
inflammation. One such mechanism is the so-called ER
overload response that can activate NF-κB activation [60,61].
Interestingly, CREBH, a recently identified ER sensor protein
expressed in hepatocytes, can directly induce expression of
acute phase proteins in response to ER stress [62]. In
addition, TNFR1 itself has been implicated in the pathway
leading from ER stress to activation of the JNK family of
mitogen-activated protein kinases [63]. In a transfection
system mutant, however, TNFR1 did not appear to directly
activate ER stress responses, so this seems less likely to be
at the crux of the disease mechanism [56].
A final possibility is that the retained receptors in TRAPS may
alter the balance between the TNFR1-initiated signalling
pathways. TNFR1 can signal via two opposing pathways that
lead to either apoptosis via caspase activation or to cellular
survival and inflammation via the activation of NF-κB
(Figure 3). Much work has been carried out to decipher how
these two opposing pathways are regulated, and it is thought
that a crucial difference in the threshold of TNF activation is
required for cytokine activation via NF-κB, or apoptosis
induction. The accepted model for TNFR1 signalling is one in
which the survival genes are the first to be activated, through
the formation of a surface-bound complex. The apoptosis
pathway occurs later, upon formation of a second intracellular
complex in receptosomes [64,65]. Interestingly, neutrophils
and dermal fibroblasts from TRAPS patients with several
different mutations undergo reduced apoptosis when
exposed to TNF [16,66]. Dermal fibroblasts derived from a
patient with the C43S mutation showed a reduced level of
apoptosis compared with normal controls, but intact produc-
tion of the proinflammatory cytokines IL-6 and IL-8 when
exposed to TNF. Failure of activated immune cells to undergo
apoptosis in TRAPS could lead to a build up of proinflam-
matory cytokines. Figure 4 illustrates the possible differences
in the trafficking and signalling of TNFR1 in TRAPS patient cells.
Conclusions
Contrary to initial findings, the systemic inflammation that is
characteristic of TRAPS may not be solely due to a defect in
receptor shedding, but instead could stem from the
consequences of misfolded and intracellularly retained
TNFR1. It is, however, possible that there is not one unifying
mechanism for all TRAPS mutations – the variability in
symptoms among patients may be a clue towards this, and
there is also a strong possibility of linked susceptibility genes.
At present, some success with anti-TNF agents is likely to
steer therapeutics in this direction – but while these thera-
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Figure 3
TNF receptor 1 signalling. TNF receptor 1 (TNFR1) ligation induces
death domain-mediated recruitment of TNFR1/TRADD/TRAF2/RIP1
(complex I) at the cell surface, and this complex initiates NF-κB
activation, which in turn drives production of cFLIP, an apoptotic
inhibitor. Activated TNFR1 is then endocytosed and the
TRADD/TRAF2/RIP1 complex dissociates from the receptor in a
temporal manner. This complex then recruits FADD and caspase-8
(complex II), which activates the apoptotic machinery, provided that the
levels of cFLIP are low enough to remove inhibition. Adapted from
[64]. In a second model, proposed by Schneider-Brachart and
colleagues [65], the apoptotic complex is internalised upon assembly
in receptosomes, which fuse with golgi vesicles and signal for
apoptosis from within the cell. NO, nitric oxide; ROS, reactive oxygen
species.
peutics may alleviate the inflammatory symptoms in some
cases, extracellular TNF blockade may not address the
underlying molecular mechanism of this disease. For the new
findings to bear fruit, it will be crucial to determine the exact
mechanism by which intracellular retention of the TRAPS
mutant TNFR1 can drive inflammation. In neurons, the
accumulation of misfolded proteins is thought to cause cell
death and play a major role in the pathogenesis of
neurodegenerative diseases, but the consequences of
misfolded proteins in immune cells has not been well studied.
Conversely, the effect of TNFR1 mutations outside immune
cells also needs to be examined. Understanding the signalling
pathways connecting protein misfolding and inflammation will
be interesting in relation to this rare genetic syndrome, and
will also be potentially relevant to more common inflammatory
conditions.
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